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Abstract: Substantial gains have been made in the control of
malaria; in many regions malaria has reached historically low
prevalence. Still the global malaria burden remains unacceptably
high and the spread of antimalarial and insecticide resistance
threatens a resurgence.
A number of malaria prevention strategies have been evaluated
since the turn of the century. Intermittent presumptive therapy
(IPT) held initially great promise but has ultimately disappointed
and has not been implemented. Seasonal malaria chemoprophy-
laxis has evolved from IPT and restricts presumptive therapy to the
months with the highest malaria incidence. This strategy is ﬁnd-
ing increasing acceptance. Malaria vaccines have a long history but
have yet to result in the roll-out of a safe, highly protective, long
lasting product. The last candidate, RTS,S/AS01 held great hope but
also has ultimately disappointed and the inclusion in the expanded
program of immunisations has not been recommended at the end
of last year. There are new vaccine candidates on the horizon but
there is no reasonable hope that a vaccine can be used to prevent
malaria on a population level in the near future.
The ultimate hope to prevent malaria has to be the elimination
of malaria. While considered unrealistic until recently a range of
novel strategies aim now at the elimination of malaria.
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Abstract: Plasmodium vivax (P.vivax) endemicity covers large
and diverse geographical regions. Transmission is lower than
Plasmodium falciparum, however, relapses caused by hypnozoite
forms increase the number of infections and sustain transmission.
Resistance against chloroquine is increasing and assessment of
efﬁcacy is confounded because recrudescence, relapse and rein-
fection cannot be distinguished reliably. Background incidence
of new P.vivax infections are needed for comparing efﬁcacy of
treatment regimens. Primaquine is the only currently widely avail-
able treatment effective against relapses (hypnozoite stage) of
P.vivax and assessment of its radical curative efﬁcacy using cur-
rently recommended dosing is required. Optimising primaquine
regimens may be necessary to improve adherence in some pop-
ulations. The assurance of primaquine safety in persons with
glucose-6-phosphate-dehydrogenase (G6PD) deﬁciency is essen-
tial if deployed universally for malaria elimination.
Methods: BetweenMarch 2010 and July 2015 a series of studies
were conducted in northwestern Thailand along the Myanmar
border. In the ﬁrst study, a rolling cohort of 200 healthy subjects
with a history of P.vivax were given primaquine for radical cure
and followed until a new P.vivax infection. The overall incidence
of new P.vivax infection was 0.13 infections per person-year. In a
parallel study 650 subjects with P.vivax malaria were randomized
to artesunate, chloroquine or chloroquine+primaquine (only G6PD
normal subjects) and followed for one year. At least one recurrence
with P.vivax occurred in over 70% subjects in non-primaquine
arms and in 18% subjects taking primaquine. The burden of
relapse was calculated to be 78%. In a third study, 680 G6PD nor-
mal subjects were randomized to chloroquine+primaquine
7 days (1mg/kg/day), chloroquine+primaquine 14 days
(0.5mg/kg/day), dihydroartemisinin-piperaquine+primaquine 7
days or dihydroartemisinin-piperaquine+primaquine 14 days.
Recurrences within one year follow up with P.vivax were
treated with a standard dose of chloroquine+primaquine 14
days (0.5mg/kg/day). Subjects with at least one recurrence were
not signiﬁcantly different between the 7 and 14-day primaquine
regimens, although non-inferiority of the 7-day regimen was
inconclusive.
Conclusion: Relapse contributes substantially to the burden of
P.vivax malaria. High dose primaquine (7mg/kg) over 7 or 14-days
are efﬁcacious and universal deployment is likely necessary for
P.vivax elimination. However, safety of these regimens in persons
with G6PD deﬁciency requires conﬁrmation.
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Abstract: Rickettsiae are obligatory intracellular bacteria, trans-
mitted to vertebrates by arthropod vectors, primarily by ﬂeas
and ticks. A rapid increase in the incidence of four endemic rick-
ettsioses; Rocky Mountain spotted fever, Mediterranean spotted
fever, North Asian tick typhus, and Queensland tick typhus was
noted since 1970s and for Japanese spotted fever, since its discov-
ery in mid-1980s. As a result, spotted fever group of rickettsiae
(SFG) currently include over 25 formally recognized species. Ele-
vated attention to rickettsial diseases, advent and adaptation of
new molecular tools used for ﬁeld and laboratory studies in the
1990s and increase in funding support have lead to this second pro-
nounced increase in the discovery of novel species and the increase
in incidence of tick-borne rickettsial diseases in the last 40 years.
Change in ecological factors which determine the vector species
